The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
Investigators used gene panel testing to assess hereditary breast and ovarian cancer risk in African American women with breast cancer, uncovering potential gaps in test access.
The draft guidance recommends access to the drug through the Cancer Drugs Fund as maintenance therapy of advanced ovarian, fallopian tube, or primary peritoneal cancer.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The study has shown that patients on Zejula had longer progression-free survival than those on placebo regardless of their BRCA1/2 mutation or HRD status.
The differing effects of BRCA mutations by tumor lineage could have ramifications for treatments targeting the DNA repair process, the research team said.
